This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kharode, Y. Articles by Komm, B. S. Search for Related Content PubMed PubMed Citation Articles by Kharode, Y. Articles by Komm, B. S.

The Pairing of a Selective Estrogen Receptor Modulator, Bazedoxifene, with Conjugated Estrogens as a New Paradigm for the Treatment of Menopausal Symptoms and Osteoporosis Prevention

Wyeth Research, Women’s Health and Musculoskeletal Biology, Collegeville, Pennsylvania 19426

Address all correspondence and requests for reprints to: Barry S. Komm, Ph.D., Senior Director, Women’s Health and Musculoskeletal Biology–Nuclear, Wyeth Research, Collegeville, Pennsylvania 19426. E-mail: KOMMB{at}wyeth.com.

The menopausal transition is associated with decreased ovarian function and concomitant decline in estrogen production, which may result in physiological effects such as hot flashes, reduced bone mass, and altered lipid profile. It is well established that these unfavorable changes are effectively offset with estrogen therapy (ET) or, in women with a uterus, estrogens in combination with a progestin (hormone therapy). Selective estrogen receptor (ER) modulators (SERMs), which exhibit both ER agonist and antagonist activities depending on the target tissue, have been regarded as offering the potential to provide the benefits of ET and hormone therapy with an improved safety and tolerability profile. To date, no SERM alone has demonstrated an ideal benefit-risk profile for menopausal therapy. The tissue-selective estrogen complex, or the pairing of a SERM with estrogens, may provide an optimal blend of ER agonist and antagonist activities. We evaluated the physiological profile of this novel therapeutic paradigm by using various in vivo models to assess uterine, vasomotor, lipid, and skeletal responses to a tissue-selective estrogen complex partnering bazedoxifene with conjugated estrogens (CE). Bazedoxifene at 3.0 mg/kg effectively antagonized CE-induced uterine stimulation without reversing the positive effects of CE on vasomotor instability. When paired with CE, bazedoxifene at 3.0 mg/kg reduced total cholesterol levels by up to 20% compared with CE alone and significantly increased total bone density relative to control. These preclinical findings showed that the appropriate dose combination of bazedoxifene/CE exhibits positive vasomotor, lipid, and skeletal responses with minimal uterine stimulation.

This article has been cited by other articles:

				B. J. Peano, J. S. Crabtree, B. S. Komm, R. C. Winneker, and H. A. Harris Effects of Various Selective Estrogen Receptor Modulators with or without Conjugated Estrogens on Mouse Mammary Gland Endocrinology, April 1, 2009; 150(4): 1897 - 1903. [Abstract] [Full Text] [PDF]

				T. J. Berrodin, K. C. N. Chang, B. S. Komm, L. P. Freedman, and S. Nagpal Differential Biochemical and Cellular Actions of Premarin Estrogens: Distinct Pharmacology of Bazedoxifene-Conjugated Estrogens Combination Mol. Endocrinol., January 1, 2009; 23(1): 74 - 85. [Abstract] [Full Text] [PDF]